KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q2 2024

Written by Emily J. Thompson, Senior Investment Analyst

Source: Business Insider

Updated: Aug 09 2024

0mins

KPRX+1.42%

Should l Buy KPRX?

Source: Business Insider

Kiora Pharmaceuticals Q2 2024 Results: Kiora Pharmaceuticals reported a second quarter earnings per share of -53 cents, surpassing the analyst estimate of -81 cents, with total revenue of $20,000.
InvestorPlace Earnings Automation: InvestorPlace Earnings utilizes automated data from TradeSmith to quickly publish key financial metrics and comparisons to analyst estimates for quarterly earnings reports.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy KPRX?" and start using high-conviction signals backed by rigorous historical data.

KPRX

$2.15+Infinity%1D

Analyst Views on KPRX

Wall Street analysts forecast KPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KPRX is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Analyst Rating

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.120

Low

12.00

Averages

12.00

High

12.00

Current: 2.120

Low

12.00

Averages

12.00

High

12.00

H.C. Wainwright

Buy

maintain

$10

2025-07-22

Reason

H.C. Wainwright

Price Target

$10

AI Analysis

2025-07-22

maintain

Buy

Reason

H.C. Wainwright reiterates a Buy rating and $10 price target on shares of Kiora Pharmaceuticals after the company announced that it received received a U.S. patent covering KIO-104 for the treatment of ocular diseases, including ocular inflammation, uveitis, age-related macular degeneration, and complications from refractive surgery. The patent covers varying dosing schedules, necessary excipients, and other novel methods for optimizing treatment of ocular inflammatory diseases, the analyst tells investors in a research note. The new patent should strengthen the company's IP portfolio and help secure the potential market prospects if KIO-104 is successfully developed in clinical studies, the firm says.

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$10

2025-03-28

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$10

2025-03-28

Reiterates

Strong Buy

Reason

About KPRX

Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders

Oct 30 2025PRnewswire

Kiora Pharmaceuticals Joins RARE-X Vision Consortium: Kiora Pharmaceuticals has partnered with Global Genes to join the RARE-X Vision Consortium, aimed at enhancing collaboration among stakeholders to develop therapies for rare ocular disorders.
Goals of the Vision Consortium: The consortium focuses on patient identification, recruitment, and developing meaningful outcome measures for clinical trials, while integrating patient voices into study designs to improve the lives of those affected by rare vision disorders.

HC Wainwright & Co. Reiterates Buy on Kiora Pharmaceuticals, Maintains $10 Price Target

Mar 28 2025Benzinga

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

HC Wainwright & Co. Reiterates Buy on Kiora Pharmaceuticals, Maintains $10 Price Target

Nov 12 2024Benzinga

Real-time Intelligence: Benzinga Pro offers traders the fastest and most accurate stock market intelligence, helping them make informed decisions daily.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and alerts generated by Benzinga reporters.

Kiora Pharmaceuticals gets approval to initiate mid-stage trial for eye disorder treatment

Oct 29 2024SeekingAlpha

Regulatory Approval: Kiora Pharmaceuticals has received approval to start a mid-stage trial for KIO-301 aimed at restoring vision in patients with retinitis pigmentosa, a genetic disorder leading to vision loss.
Trial Details: The ABACUS-2 trial will involve 36 patients and is designed as a multi-center, double-masked, randomized, controlled study focusing on individuals with ultra-low vision or no light perception.

Buy Rating on Kiora Pharmaceuticals: Strong Financials and Promising KIO-301 Progress

Aug 10 2024Business Insider

Analyst Rating: Michael Okunewitch of Maxim Group maintains a Buy rating on Kiora Pharmaceuticals (KPRX) with a price target of $27.00, citing the company's strong financial position and promising drug development, particularly for its lead asset KIO-301 aimed at restoring vision in retinal disease patients.
Company Overview: Kiora Pharmaceuticals is a clinical stage specialty pharmaceutical company focused on eye diseases, with sufficient funding to support its operations until 2027 and a strategic partnership with Laboratoires Théa enhancing its commercial prospects.